AAVnerGene Launches AAVone® 2.1, a Next-Generation Single-Plasmid AAV Production Platform
New Platform Launch and Technological Significance
AAVnerGene has officially launched AAVone® 2.1, its next-generation single-plasmid AAV production platform. Existing gene therapy manufacturing processes primarily rely on triple transfection, which involves introducing three plasmids into cells. This method has been hampered by complex processes and high costs. AAVone® 2.1 integrates the genetic elements required for viral production into a single plasmid, significantly improving process efficiency. This reflects the market's demand to reduce the cost of gene therapy production and address bottlenecks in large-scale manufacturing.
Breakthrough in Productivity and Quality Metrics
The newly released AAVone® 2.1 platform achieves a high titer of approximately 1e16 genome copies per liter (GC/L) in cell culture. It also ensures that more than 70% of the harvested material consists of full capsids, which contain the therapeutic gene. Traditional production methods often result in a high proportion of empty capsids, necessitating additional purification steps. This platform provides high purity from the initial harvest, reducing the burden on the purification process and maximizing cost-effectiveness.
Expanding Market Access Through Reduced Manufacturing Costs
The simplified process based on a single plasmid significantly reduces the cost of DNA raw materials and the use of delivery materials such as liposomes. By addressing the plasmid supply issue, which accounts for a significant portion of the cost of gene therapy manufacturing, this platform can lower the barriers to clinical entry for small and medium-sized biotechnology companies. Furthermore, it can be universally applied to various serotypes and engineered AAV capsids, making it highly versatile. Ultimately, this will provide a foundation for delivering high-priced gene therapies to patients at a reasonable cost.
Technological Differentiation in the Global CDMO Competitive Landscape
The AAV contract development and manufacturing organization (CDMO) market is currently highly competitive, with players such as Viralgen, which utilizes AskBio's Pro10™ cell line, and Minaris Advanced Therapies, with its TESSA® platform. Compared to these competing platforms, AAVnerGene's AAVone® 2.1 offers a unique advantage by reducing the dependence on plasmid supply chains by one-third while producing high-purity vectors. In particular, it can shorten complex purification processes, providing a strategic advantage in terms of production time (turnaround time) compared to competitors.
Growth Potential of the Platform Business
AAVnerGene plans to combine this platform with its proprietary HEK293one cell line and pursue joint development and licensing agreements with global bio companies. With the global AAV gene therapy market expected to reach approximately $3.7 billion to $5.4 billion by 2026, and the AAV manufacturing market projected to reach $1.4 billion to $3.2 billion, the commercial potential of the platform is significant. Although it is not a publicly listed company, this technological innovation is expected to significantly increase the company's value by securing large milestone payments and long-term royalty revenue streams.
The AAVone® 2.1 platform, targeting the AAV vector manufacturing market projected to reach $1.4 billion to $3.2 billion by 2026, maximizes manufacturing efficiency by achieving a high titer of 1e16 GC/L or higher and a full capsid ratio exceeding 70% through single-plasmid technology. This provides a significant reduction in raw material and purification costs compared to the triple transfection process used by competitors such as Viralgen. Gene therapy researchers and manufacturers can reduce the burden of high production costs and prevent the chronic production delays that occur in preclinical and clinical development stages and commercialization. In the long term, it will be a key driver for improving the scalability and commercial viability of the gene therapy market by significantly reducing the price of expensive rare disease gene therapies.